GSK
GSK
764 hedge funds and large institutions have $9.69B invested in GSK in 2017 Q4 according to their latest regulatory filings, with 135 funds opening new positions, 167 increasing their positions, 348 reducing their positions, and 109 closing their positions.
24% more first-time investments, than exits
New positions opened: 135 | Existing positions closed: 109
3% more funds holding
Funds holding: 742 → 764 (+22)
8% more call options, than puts
Call options by funds: $108M | Put options by funds: $100M
0.46% more ownership
Funds ownership: 3.95% → 4.41% (+0.46%)
2% less capital invested
Capital invested by funds: $9.86B → $9.69B (-$168M)
10% less funds holding in top 10
Funds holding in top 10: 10 → 9 (-1)
52% less repeat investments, than reductions
Existing positions increased: 167 | Existing positions reduced: 348
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Dodge & Cox
San Francisco,
California
|
+$1.08B |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$624M |
| 3 |
Two Sigma Advisers
New York
|
+$66.9M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$55.4M |
| 5 |
Millennium Management
New York
|
+$48.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$197M |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$125M |
| 3 |
HCM
Hamlin Capital Management
New York
|
-$72M |
| 4 |
MHI
Miller Howard Investments
Kingston,
New York
|
-$56.4M |
| 5 |
Morgan Stanley
New York
|
-$38.2M |
GSK Hedge Fund Activity: Q4 2017 in Review
764 of the 4,419 institutional investors tracked by Wall St. Rank reported a position in GSK (GSK) for Q4 2017, worth a combined $9.69B — down 1.7% from $9.86B a quarter earlier.
Buyers outnumbered sellers: 135 funds opened new GSK positions and 109 closed out — a net gain of 26 holders — while 167 added to existing stakes and 348 trimmed.
The largest buyer was Dodge & Cox, adding an estimated $1.08B. The largest seller was Wells Fargo, cutting an estimated $197M.
- 764 institutional investors held GSK (GSK) as of Q4 2017, up from 742 in Q3 2017.
- Funds reported $9.69B of GSK stock for Q4 2017, down 1.7% quarter-over-quarter.
- 135 funds opened new GSK positions in Q4 2017 and 109 closed out, a net change of +26 holders.
- The largest GSK buyer in Q4 2017 was Dodge & Cox, an estimated $1.08B added.
- The largest GSK seller in Q4 2017 was Wells Fargo, an estimated $197M sold.
Based on aggregated 13F filings for Q4 2017.